(Q41008169)

25 September 2017

title

Inhibition of SN-38 glucuronidation by gefitinib and its metabolite (English)

1 reference

7-ethyl-10-hydroxycamptothecin

25 September 2017

main subject

1 reference

ChEBI release 2020-05-28

Wei Li

1

1 reference

25 September 2017

Yafei Xing

series ordinal

2

1 reference

25 September 2017

Yong Liu

series ordinal

3

1 reference

25 September 2017

language of work or name

1 reference

28 April 2015

1 reference

Cancer Chemotherapy and Pharmacology

25 September 2017

published in

1 reference

25 September 2017

volume

75

1 reference

25 September 2017

issue

6

1 reference

25 September 2017

page(s)

1253-1260

1 reference

Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

UDP-glucuronosyltransferases and clinical drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Gefitinib increases serum concentrations of oral irinotecan and SN-38 without increasing the biliary concentration of SN-38 in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

Gefitinib in Combination with 5-Fluorouracil (5-FU)/Folinic Acid and Irinotecan in Patients with 5-FU/Oxaliplatin- Refractory Colorectal Cancer: A Phase I/II Study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2753-4

10.1007/S00280-015-2753-4

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

25 September 2017

1009484031

0 references

1 reference